Company news
RenovoRx, Inc. news in 2023
RenovoRx, Inc.'s news releases, calls and decks from 2023, newest first.
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
December 20, 2023
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
December 18, 2023
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
December 12, 2023
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
November 15, 2023
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
November 13, 2023
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
October 1, 2023
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
August 16, 2023
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
July 30, 2023
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
July 19, 2023
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
July 19, 2023
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
June 28, 2023
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
June 19, 2023
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
May 14, 2023
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
April 30, 2023
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
April 26, 2023
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
April 13, 2023
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
April 10, 2023
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
March 29, 2023
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
March 29, 2023
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
March 1, 2023
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
January 17, 2023
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
January 4, 2023
Decks in 2023
- Technical Presentation (2023)
Technical · 19 slides · 2023